PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Shanu Modi, MD - Navigating Shifts in the Treatment Landscape for Metastatic HER2-Positive Breast Cancer: Can New HER2-Targeted Therapies Address Unmet Needs and Offer Better Options for Challenging Patient Populations?
Go online to PeerView.com/FXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, medical oncologists discuss the latest advances in managing patients with HER2-positive breast cancer, including an overview of approved and emerging HER2-targeted therapies, and share perspectives on novel targeted therapies and combinations that may improve outcomes in challenging patient subgroups. In addition, practical guidance is offered to help facilitate the integration of the latest HER2-targeted therapies into individualized treatment plans for patients with breast cancer. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the characteristics, mechanisms of action, efficacy/safety profiles, and potential clinical roles of approved and investigational HER2-targeted therapies for metastatic HER2-positive breast cancer, Review the clinical evidence on novel HER2-targeted therapies and combinations that may offer new treatment options to challenging patient subgroups that are unlikely to benefit from currently available HER2-directed therapies (eg, patients with CNS metastases, low HER2 expression), Integrate the latest HER2-targeted therapies into individualized treatment plans for appropriate patients with metastatic HER2-positive breast cancer either in the context of clinical practice or through clinical trial participation.